Index Introduction Dear Fellow Shareholders Our Products Product Characteristics Republic of South Africa Approval Accredited Medical Education Program  Physician Q&A Phase III Clinical Trials U.S. Market Opportunity Medical Readiness 2001 Highlights Form 10-K Biopure Corporate Information Shareholder Information

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION     Item 1.Business     Item 2.Properties     Item 3.Legal Proceedings     Item 4.Submission of Matters to a Vote of Security Holders PART II     Item 5.Market for Registrant’s Common Equity and Related Stockholder Matters     Item 6.Selected Financial Data     Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations     Item 7A.Quantitative and Qualitative Disclosure About Market Risk     Item 8.Financial Statements and Supplementary Data     Item 9.Changes In and Disagreements With Accountants on Accounting and Financial Disclosure PART III PART IV     Item 14.Exhibits, Financial Statement Schedules, and Reports on Form 8-K EXHIBIT INDEX SIGNATURES INDEX TO CONSOLIDATED FINANCIAL STATEMENTS REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS CONSOLIDATED BALANCE SHEETS CONSOLIDATED STATEMENTS OF OPERATIONS CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY CONSOLIDATED STATEMENTS OF CASH FLOWS NOTES TO CONSOLIDATED FINANCIAL STATEMENTS